10:59 AM EDT, 10/08/2025 (MT Newswires) -- Eli Lilly ( LLY ) is projected to report Q3 results broadly in line with Wall Street expectations, driven by a strong performance from diabetes drug Mounjaro and steady demand for obesity treatment Zepbound, Deutsche Bank said in a report Wednesday.

Mounjaro is forecast to post a "solid 3Q25 beat" with resilient pricing, while Zepbound is seen performing "in line" after earlier headwinds from CVS Health's ( CVS ) decision to exclude it from its "template plans." Softer results from Verzenio, Taltz and Jardiance may offset those gains, the report said.

Revenue for the quarter is expected to align with Bloomberg's consensus of about $16.1 billion, while non-GAAP earnings per share are estimated at $6.29, "a penny below" Bloomberg's consensus. Analysts at Deutsche Bank at expect the company to reiterate its full-year 2025 revenue guidance of $60 billion to $62 billion and maintain its non-GAAP EPS outlook of $21.75 to $23.00, the report said.

Deutsche Bank said investors are looking beyond quarterly earnings to policy and product catalysts, including a potential White House announcement on a Most-Favored Nation Medicaid drug price deal and key milestones such as Orforglipron's approval progress, interim data from Alzheimer's candidate TB-ALZ3, and obesity drug updates at "Obesity Week" in November.

Deutsche Bank has a buy rating on Eli Lilly ( LLY ), with a price target of $900.

Price: 850.73, Change: +7.10, Percent Change: +0.84